Massive study pits diabetes drugs against each other for heart protection
NCT ID NCT07096063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at real-world medical records from over 887,000 people with type 2 diabetes, overweight, and heart risk to compare two drugs: tirzepatide and semaglutide. The goal was to see which one better prevents serious heart problems like heart attack, stroke, or death. The study did not give anyone new treatment but instead analyzed existing data to learn how to use real-world information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States